<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086110</url>
  </required_header>
  <id_info>
    <org_study_id>450072</org_study_id>
    <nct_id>NCT02086110</nct_id>
  </id_info>
  <brief_title>Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism</brief_title>
  <official_title>A Pilot Study Examining Microbiota Composition in Children With Autism and Gastrointestinal Symptoms After Use of Bifidobacterium Infantis and Milk Oligosaccharides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability of dietary supplements and if
      these supplements can promote a healthy bacterial environment in the intestines of children
      with autism spectrum disorders and gastrointestinal complaints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the feasibility, tolerability, and effects of a dietary supplement on
      the intestinal flora of children with autism spectrum disorders. This study is divided into
      two parts, each five weeks long, with a two week break in between. During one part of the
      study, a prebiotic (milk oligosaccharides from bovine colostrum) will be given. During the
      other part of the study, the synbiotic composed of the prebiotic and probiotic
      (bifidobacterium infantis) will be given. Stool will be analyzed at the end of each study arm
      to determine content of bifidobacteria.

      On May 8, 2018, we updated the study start and completion dates to the actual (instead of
      anticipated) dates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2014</start_date>
  <completion_date type="Actual">November 16, 2015</completion_date>
  <primary_completion_date type="Actual">November 16, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool Microbiota Composition</measure>
    <time_frame>Five weeks</time_frame>
    <description>The stool microbiome composition will be analyzed through next generation sequencing and quantitative polymerase chain reaction. Both the overall bacterial composition will be analyzed as well as specific Bifidobacteria species present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Immune Profile</measure>
    <time_frame>5 weeks</time_frame>
    <description>Luminex technology will be used to determine a serum immune profile of each participants in response to the study supplement. This profile will include pro-inflammatory cytokines (IFNg, IL-1, IL-6, IL-13 and TNFa) and anti-inflammatory cytokines (IL-10 and TGFb1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobin Level</measure>
    <time_frame>Five weeks</time_frame>
    <description>An ELISA (enzyme-linked immunosorbent assay) will be used to determine participants' immunoglobulin (Ig) levels (IgA, IgG and IgM) in response to the study supplement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_label>Synbiotic first</arm_group_label>
    <other_name>Bifidobacterium infantis SC268</other_name>
    <other_name>bovine colostrum, bovine oligosaccharides</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_label>Synbiotic first</arm_group_label>
    <other_name>bovine colostrum, bovine oligosaccharides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autism

          -  Diarrhea and/or constipation

        Exclusion Criteria:

          -  Milk protein or other documented food allergy

          -  Lactose intolerance

          -  Compromised Immunity

          -  GI conditions (inflammatory bowel disease, celiac disease, short gut, etc.)

          -  Systemic steroid, antifungal, or antibiotic use within a month of starting the study

          -  Failure to thrive

          -  Medically prescribed diets or supplements (including probiotic use within the past
             month).

          -  Vegetarian or dairy restricted diet

          -  Other medical conditions (seizures, genetic disorders, liver/pancreatic disease,
             cystic fibrosis, etc.)

          -  Medications that interfere or alter intestinal motility or microbiota composition.

          -  Full scale intelligence quotient (IQ) &lt;40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Angkustsiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis MIND Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>prebiotic</keyword>
  <keyword>autism</keyword>
  <keyword>oligosaccharides</keyword>
  <keyword>Bifidobacterium infantis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

